Get the Stockscreener App
2.05
1.91%
-0.04
Kiora Pharmaceuticals Inc stock is traded at $2.05, with a volume of 19,379.
It is down -1.91% in the last 24 hours and down -5.09% over the past month.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$2.09
Open:
$2.1
24h Volume:
19,379
Relative Volume:
0.37
Market Cap:
$7.54M
Revenue:
-
Net Income/Loss:
$2.81M
P/E Ratio:
-0.1429
EPS:
-14.3497
Net Cash Flow:
$7.14M
1W Performance:
-1.44%
1M Performance:
-5.09%
6M Performance:
-23.22%
1Y Performance:
-41.60%
1-Day Range:
$2.05
$2.10
1-Week Range:
$2.01
$2.11
52-Week Range:
$1.7645
$4.18
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals Inc
Sector
Industry
Phone
858-224-9600
Address
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.05 | 7.69M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.62 | 119.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.54 | 83.75B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
847.74 | 52.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
337.20 | 44.12B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
355.92 | 39.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
Kiora Pharmaceuticals Inc Stock (KPRX) Latest News
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - TMX Newsfile
Can Kiora Pharmaceuticals Inc. stock hit record highs againWeekly Risk Summary & Fast Entry and Exit Trade Plans - mfd.ru
Weekly Earnings: Whats the profit margin of Kiora Pharmaceuticals IncJuly 2025 Short Interest & Weekly High Return Stock Opportunities - baoquankhu1.vn
Comparing Kiora Pharmaceuticals (NASDAQ:KPRX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN) - Defense World
Quarterly Earnings: Can MicroSectors Gold Miners 3X Leveraged ETNs due June 29 2040 continue delivering strong returnsTrend Reversal & Target Return Focused Picks - baoquankhu1.vn
Volatility Watch: Is Kiora Pharmaceuticals Inc a defensive stockBond Market & Daily Entry Point Trade Alerts - baoquankhu1.vn
Is Kiora Pharmaceuticals Inc still a buy after recent gains2025 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Kiora Pharmaceuticals adds retina specialist to advisory board By Investing.com - Investing.com Canada
Why a leading retinal surgeon is backing new non-steroid eye drugs - Stock Titan
Update Recap: Does Kiora Pharmaceuticals Inc have pricing power2025 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Trade Recap: Does Kiora Pharmaceuticals Inc have consistent dividend growthMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Can Kiora Pharmaceuticals Inc. stock surprise with earnings upsideDividend Aristocrats List & Outperform With Our Smart Trading Calculator - Bollywood Helpline
Institution Moves: Can ADS TEC Energy PLC Equity Warrant deliver alphaEarnings Growth Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Fund Flows: Is Kiora Pharmaceuticals Inc stock supported by innovation pipeline2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - Bộ Nội Vụ
Will Kiora Pharmaceuticals Inc. stock deliver better than expected guidanceMarket Movers & Weekly Stock Performance Updates - Улправда
Will Kiora Pharmaceuticals Inc. (7EY) stock announce a stock splitTrade Ideas & Risk Controlled Daily Plans - Улправда
Why Kiora Pharmaceuticals Inc. (7EY) stock trades below fair valueJuly 2025 Closing Moves & Weekly Market Pulse Updates - Улправда
Is Kiora Pharmaceuticals Inc. stock supported by strong fundamentalsWeekly Trend Recap & Weekly Consistent Profit Watchlists - ulpravda.ru
Kiora Pharmaceuticals, Inc.Common Stock (NQ: KPRX - FinancialContent
Pyxis Oncology (NASDAQ:PYXS) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Contrast - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.5% Higher – What’s Next? - Defense World
Kiora Pharmaceuticals (KPRX) Stock Analysis Report | Financials & Insights - Benzinga Italia
Aug Intraday: What momentum indicators show for CALX stockPortfolio Gains Summary & Fast Gain Stock Tips - moha.gov.vn
Will Kiora Pharmaceuticals Inc. stock reach all time highs in 2025Weekly Trade Review & Target Return Focused Stock Picks - Улправда
Is Kiora Pharmaceuticals Inc. stock a defensive play in 2025Weekly Stock Analysis & Free Risk Controlled Daily Trade Plans - Улправда
Will Kiora Pharmaceuticals Inc. stock rally after Fed decisionsJuly 2025 EndofMonth & Weekly Return Optimization Plans - Улправда
Is Kiora Pharmaceuticals Inc. stock overvalued by current metrics2025 Stock Rankings & Verified Momentum Stock Ideas - Улправда
How Kiora Pharmaceuticals Inc. stock reacts to bond yields2025 Volatility Report & Safe Entry Trade Reports - DonanımHaber
Why analysts upgrade Kiora Pharmaceuticals Inc. stockJuly 2025 Action & Free High Accuracy Swing Entry Alerts - Улправда
How Kiora Pharmaceuticals Inc. stock benefits from global expansionStock Surge & Free Growth Oriented Trading Recommendations - DonanımHaber
Can Kiora Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - Улправда
Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website - TMX Newsfile
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - TMX Newsfile
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study - TMX Newsfile
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years - TMX Newsfile
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million - TMX Newsfile
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini - TMX Newsfile
Aug Decliners: Is Kiora Pharmaceuticals Inc. stock a defensive play in 2025Swing Trade & Intraday High Probability Alerts - Улправда
The Biotech Tug-of-War: Is Kiora Pharmaceuticals Positioned to Ride the 2025 Commodity Wave? - FinancialContent
Kiora Pharmaceuticals Earnings Notes - Trefis
Aug Rallies: How geopolitical tensions affect Kiora Pharmaceuticals Inc stock2025 Bull vs Bear & Community Consensus Trade Signals - moha.gov.vn
Kiora Pharmaceuticals, Inc. (KPRX) AI-Powered Stock Analysis - Meyka
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 0.5% – Should You Sell? - Defense World
Will Kiora Pharmaceuticals Inc. (7EY) stock beat Nasdaq index returnsQuarterly Trade Report & Proven Capital Preservation Methods - Newser
How Kiora Pharmaceuticals Inc. (7EY) stock reacts to new regulationsJuly 2025 Recap & Expert Approved Momentum Ideas - Newser
Is Kiora Pharmaceuticals Inc. (7EY) stock cheap vs fundamentalsJuly 2025 Intraday Action & Free AI Powered Buy and Sell Recommendations - Newser
Will Kiora Pharmaceuticals Inc. stock benefit from commodity prices2025 Technical Overview & Expert Verified Stock Movement Alerts - Newser
Kiora Pharmaceuticals receives new patent for KIO-100 formulations By Investing.com - Investing.com Nigeria
Kiora Pharmaceuticals receives new patent for KIO-100 formulations - Investing.com
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds - TMX Newsfile
Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):